Benign Prostatic Hyperplasia Updated Treatment and Prevention Management
Article Sidebar
Main Article Content
Abstract
Background: Benign prostatic hyperplasia (BPH) is a histologic diagnosis which referred to a proliferation of ephitelial and smooth muscle tissues in the transitional zone of the prostate. BPH affects roughly 18-25% of all male aged 40 years and above and 90% of all male aged beyond 80. BPH is known to be able to significantly decrease quality of life and hence people with BPH need treatments to help them alleviate its effects.
Methods: The research was conducted using literature review from the most actual and respected clinical guidelines, scientific literatures, websites, and textbooks on BPH.
Discussion: There are three main groups of treatment, which are conservative, pharmacological, and surgical treatments. Treatment should be chosen from the least invasive first with the aim of increasing quality of life. Even if it is hard to prevent, several preventive measures could be conducted, such as limiting usage of BPH-inducing drugs, doing healthy lifestyle which involves no smoking, active exercise, body weight control, and balanced diet.
Conclusion: BPH is a very prevalent condition on elderly male population. Even though it is not deadly, a proper treatment management need to be done by virtue of its ability to significantly decrease quality of life.
Article Details
References
2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016 Aug;43(3):289–97.
3. Scher H, Eastham J. Benign and malignant diseases of the prostate. In: Harrison’s principles of internal medicine. 20th ed. New York: McGraw Hill Education; 2018. p. 623–32.
4. Mochtar C, Umbas R, Soebadi D, Rasyid N, Noegroho B, Poernomo BB, et al. Panduan penatalaksanaan klinis pembesaran prostat jinak (benign prostatyic hyperplasia/BPH). 2nd ed. Jakarta: Ikatan Ahli Urologi Indonesia; 2015. 12–25 p.
5. Stelzner S. Intraoperative management of iris prolapse [Internet]. American academy of ophthalmology. 2019 [cited 2020 Aug 30]. Available from: http://eyewiki.aao.org/Intraoperative_Management_of_Iris_Prolapse
6. Lue T. Male sexual dysfunction. In: Smith & Tanagho’s general urology. 18th ed. New York: McGraw Hill Education; 2013. p. 600, 610.
7. Pattanaik S, Mavuduru R, Panda A, Matthew J, Agarwal M, Hwang E, et al. Phosphodiesterase inhibitors for lower urinary tract symptims consistent with benign prostatic hyperplasia. Urol Clin North Am. 2018 Nov 16;(11).
8. National Cancer Institute. TURP [Internet]. National Cancer Institute. 2011 [cited 2020 Sep 1]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms
9. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008 Apr 15;167(8):925–34.
10. Roehrborn C. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 2440–4.